Literature DB >> 6459300

Experimental replacement of vena cava with expanded polytetrafluoroethylene graft.

K Esato, K Shintani, S Yasutake, T Morita.   

Abstract

Expanded polytetrafluoroethylene (Gore Tex) grafts were used for the replacement of the superior or inferior vena cava in dogs. When examined 2 weeks to 18 months after the replacement, the overall patency rate was 82%. If neither deformation nor narrowing of the graft on examination by cavagram had occurred within 14 days after implantation, the patency of the grafts remained unchanged. Ninety days after implantation, the formation of pseudointima was almost complete. However, since the grafts were not firmly anchored, superficial desquamation in their mid-portion continued for long periods. A composite graft made up of Gore Tex and noncrimped Dacron was studied in order to know the reason why high patency of the Gore Tex graft was obtained. The pseudointima of the Gore Tex graft gradually increased in thickness for 60 min, after which no further increase was observed. The pseudointima in the Dacron graft thickened markedly as time progressed and additional layers of blood cells accumulated on it. Although the ultimate fate of Gore Tex graft has not yet been determined, experimental trials indicate its suitability for patients requiring replacement of the vena cava.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6459300

Source DB:  PubMed          Journal:  Int Surg        ISSN: 0020-8868


  2 in total

1.  High-porosity expanded polytetrafluoroethylene grafts for thoracic vena cava replacement with or without an omentum wrap.

Authors:  T Nishibe; K Yasuda; H Ohkashiwa; S Watanabe; Y Okuda; T Tanabe
Journal:  Surg Today       Date:  2000       Impact factor: 2.549

2.  Portal vein reconstruction with conventional polytetrafluoroethylene grafts: an experimental study in dogs.

Authors:  T Nishibe; H Manase; K Miyazaki; H Ohkashiwa; Y Satoh; S Watanabe; T Takahashi; H Katoh; Y Okuda; T Tanabe
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.